Express News | GlycoMimetics Inc -on June 21, Got Notice From Nasdaq, Co Is Not in Compliance With Nasdaq’s Listing Rule 5450(a)(1)
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
Even if it's not a huge purchase, we think it was good to see that Edwin Rock, the Senior VP & Chief Medical Officer of GlycoMimetics, Inc. (NASDAQ:GLYC) recently shelled out US$79k to buy stock, at U
Beyond Air XAIR Earnings; GlycoMimetics GLYC Insider Buys
Why GlycoMimetics Stock Is Trading Higher Monday
GlycoMimetics, Inc. (NASDAQ:GLYC) stock is moving higher Monday after its chief medical officer disclosed the purchase of company stock. The Details: On Tuesday, the chief medical officer Edwin Rock
Trending Stocks Today: Volcon Soars 77.31% Pre-Market
June 25th - US stocks trending pre-market: Gainers: $Volcon(VLCN.US)$ soars 77.31% to $6.88 with a turnover of $13.82 million. $GlycoMimetics(GLYC.US)$ surges 43.47% to $0.38 with a turnover of $5.9 m
Trending Stocks Today: GlycoMimetics Shoots up 79.66% Post-Market
June 24th - US stocks trending post-market.Gainers: $GlycoMimetics(GLYC.US)$ shoots up 79.66% to $0.48 with a turnover of $8.3 million. $Recursion Pharmaceuticals(RXRX.US)$ climbs 4.38% to $9.75 with
GlycoMimetics(GLYC.US) Officer Buys US$78,824.5 in Common Stock
$GlycoMimetics(GLYC.US)$ Officer Rock Edwin purchased 305K shares of common stock on Jun 20, 21, 2024 at an average price of $0.2584 for a total value of $78,824.5.Source: Announcement What is stateme
Express News | GlycoMimetics Shares Are Trading Higher After the Company Disclosed That Chief Medical Officer Edwin Rock Bought 305,000 Shares at an Average Price of $0.26 per Share
GlycoMimetics Form 4 Filing Shows CMO Edwin Rock Bought 305,000 Shares At An Average Price Of $0.26/Share
GlycoMimetics Form 4 Filing Shows CMO Edwin Rock Bought 305,000 Shares At An Average Price Of $0.26/Share
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones index closed higher by around 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and trader
GlycoMimetics(GLYC.US) Officer Buys US$4,334.75 in Common Stock
$GlycoMimetics(GLYC.US)$ Officer Hahn Brian M. purchased 17,500 shares of common stock on Jun 18, 2024 at an average price of $0.2477 for a total value of $4,334.75.Source: Announcement What is statem
Capital One Financial Maintains GlycoMimetics(GLYC.US) With Hold Rating, Maintains Target Price $0.5
Capital One Financial analyst Naureen Quibria maintains $GlycoMimetics(GLYC.US)$ with a hold rating, and maintains the target price at $0.5.According to TipRanks data, the analyst has a success rate o
HC Wainwright & Co. Reiterates Neutral on GlycoMimetics
HC Wainwright & Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:GLYC) with a Neutral.
H.C. Wainwright Maintains GlycoMimetics(GLYC.US) With Hold Rating
H.C. Wainwright analyst Edward White maintains $GlycoMimetics(GLYC.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 30.5% and a total average return of -14.2% over
Express News | GlycoMimetics Shares Are Trading Higher After the Company Announced Results From Its Phase 3 Study of Uproleselan in R/R AML Demonstrating a Clinically Meaningful Improvement in Median Overall Survival
Express News | GlycoMimetics-Advancing Discussion With Nci,Alliance for Clinical Trials in Oncology Based on Results of Pivotal Phase 3 Study of Uproleselan in R/R Aml
Express News | GlycoMimetics Announces Comprehensive Results From Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml)
GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it wil
GlycoMimetics GAAP EPS of -$0.17 In-line
GlycoMimetics | 10-Q: Quarterly report